Display options
Cite
Donnelly BJ, Saliken J, McDougall L, et al. Pilot study to determine safety and short-term outcome of percutaneous cryoablation in the treatment of localized prostate cancer (stages T1C-T3C NO MO). Can J Urol. 1996;3(4):261-267
Donnelly, B. J., Saliken, J., McDougall, L., & Temple, W. J. (1996). Pilot study to determine safety and short-term outcome of percutaneous cryoablation in the treatment of localized prostate cancer (stages T1C-T3C NO MO). The Canadian journal of urology, 3(4), 261-267.
Donnelly, Bryan J., et al. "Pilot study to determine safety and short-term outcome of percutaneous cryoablation in the treatment of localized prostate cancer (stages T1C-T3C NO MO)." The Canadian journal of urology vol. 3,4 (1996): 261-267.
Donnelly BJ, Saliken J, McDougall L, Temple WJ. Pilot study to determine safety and short-term outcome of percutaneous cryoablation in the treatment of localized prostate cancer (stages T1C-T3C NO MO). Can J Urol. 1996 Nov;3(4):261-267. PMID: 12741960.
Copy Download .nbib Format: NLM
Share it on

Can J Urol. 1996 Nov;3(4):261-267.

Pilot study to determine safety and short-term outcome of percutaneous cryoablation in the treatment of localized prostate cancer (stages T1C-T3C NO MO).

The Canadian journal of urology

Bryan J. Donnelly, John Saliken, Laura McDougall, Walley J. Temple

Affiliations

  1. Department of Surgery, Faculty of Medicine, University of Calgary, Calgary, Alberta.

PMID: 12741960

Abstract

OBJECTIVE: To assess the effectiveness of cryoablation in localized prostate cancer in our hands. Early end points are biopsy at 5 months and PSA at 12 months follow-up. METHODS: Percutaneous transperineal cryoablation was performed on 30 patients. A urethral warming catheter was used. All cases were newly diagnosed with no prior radiotherapy, or neoadjuvant hormones. A single freeze cycle was used in the first 10 cases and two cycles in the next 20 cases. RESULTS: Twenty-nine of 30 cases are eligible for follow-up. Six of the first 10 patients had negative biopsies, the 4 positive patients have had repeat cryoablation and only 1 patient remains biopsy positive. In cases 11-30, there were two patients with positive biopsies – both retreated. At this time, 27/29 patients (93%) have a negative biopsy after one (23 patients) or two (6 patients) treatments. At 6 months, 20/29 patients (69%) have undetectable PSA; 25/29 have PSA less than 1 ng/ml. At 12 months, 17/23 cases have an undetectable PSA (74%). Complications were minimal; 3 cases (10%) suffered urethral sloughing requiring TURP. CONCLUSION: Early results are very encouraging, showing 93% negative biopsy rate after one (23 patients) or two (6 patients) treatments; PSA is undetectable in 74% (17/23 patients) at 1 year. Early results of cryoablation for prostate cancer are encouraging.

Publication Types